Solas BioVentures
SlowingChattanooga, TNHealthcare, BiotechnologyLast fund filed October 2022
4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Solas BioVentures Emerging Healthcare Fund | October 2022 | Indefinite | $35M | 26 |
| Solas BioVentures Fund II | June 2020 | Indefinite | $35M | 88 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David Belitz | Slowing | Sales & marketing tech, Medical devices | 3 | 1 |
| Charles AdairNot on the current fund | Quiet | None listed | 0 | 0 |
| David Adair | Quiet | Medical devices, Biotech & pharma, Digital health | 13 | 0 |
| Mark Hackett | Quiet | Medical devices, Biotech & pharma | 3 | 0 |
| Michael Hoey | Quiet | Medical devices | 2 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Classified sectors of Solas BioVentures’s own portfolio companies, based on 18 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Solas BioVentures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Arboretum Ventures | 2 | Francis Medical, NXTHERA |
| Sante Health Ventures | 2 | BIOSTABLE SCIENCE & ENGINEERING, CryOSA |
| ARCH Venture Partners | 1 | Basking Biosciences |
| OCA Ventures | 1 | NX Prenatal |
A shared board seat: a company where filings name a Solas BioVentures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.